Skip to main content

Advertisement

Fig. 7 | Journal of Translational Medicine

Fig. 7

From: Development of a novel ssDNA aptamer targeting neutrophil gelatinase-associated lipocalin and its application in clinical trials

Fig. 7

The ELAA method established with NA53 aptamers can distinguish AKI patients in clinical samples. a NGAL protein level in AKI patients is significantly higher than its level in healthy samples after application of the ELAA method with NA53 aptamers. b NGAL protein diagnostic value and ROC curve analysis. c The level of NGAL protein in urine of 4 AKI patients decreased from the acute phase to recovery phase with the ELAA method, which is consistent with the change of creatinine (each colour in the figure represents one patient with AKI)

Back to article page